The safety profile observed was consistent with findings from other incretin-based therapies, particularly similar to the safety profile of GLP-1RA like liraglutide and semaglutide used for obesity treatment [27, 42]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.